TY - JOUR
T1 - Liquid biopsy biomarkers in urine
T2 - A route towards molecular diagnosis and personalized medicine of bladder cancer
AU - Ferro, Matteo
AU - La Civita, Evelina
AU - Liotti, Antonietta
AU - Cennamo, Michele
AU - Tortora, Fabiana
AU - Buonerba, Carlo
AU - Crocetto, Felice
AU - Lucarelli, Giuseppe
AU - Busetto, Gian Maria
AU - Del Giudice, Francesco
AU - de Cobelli, Ottavio
AU - Carrieri, Giuseppe
AU - Porreca, Angelo
AU - Cimmino, Amelia
AU - Terracciano, Daniela
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - Bladder cancer (BC) is characterized by high incidence and recurrence rates together with genomic instability and elevated mutation degree. Currently, cystoscopy combined with cytology is routinely used for diagnosis, prognosis and disease surveillance. Such an approach is often associated with several side effects, discomfort for the patient and high economic burden. Thus, there is an essential demand of non-invasive, sensitive, fast and inexpensive biomarkers for clinical management of BC patients. In this context, liquid biopsy represents a very promising tool that has been widely investigated over the last decade. Liquid biopsy will likely be at the basis of patient selection for precision medicine, both in terms of treatment choice and real-time monitoring of therapeutic effects. Several different urinary biomarkers have been proposed for liquid biopsy in BC, including DNA methylation and mutations, protein-based assays, non-coding RNAs and mRNA signatures. In this review, we summarized the state of the art on different available tests concerning their potential clinical applications for BC detection, prognosis, surveillance and response to therapy.
AB - Bladder cancer (BC) is characterized by high incidence and recurrence rates together with genomic instability and elevated mutation degree. Currently, cystoscopy combined with cytology is routinely used for diagnosis, prognosis and disease surveillance. Such an approach is often associated with several side effects, discomfort for the patient and high economic burden. Thus, there is an essential demand of non-invasive, sensitive, fast and inexpensive biomarkers for clinical management of BC patients. In this context, liquid biopsy represents a very promising tool that has been widely investigated over the last decade. Liquid biopsy will likely be at the basis of patient selection for precision medicine, both in terms of treatment choice and real-time monitoring of therapeutic effects. Several different urinary biomarkers have been proposed for liquid biopsy in BC, including DNA methylation and mutations, protein-based assays, non-coding RNAs and mRNA signatures. In this review, we summarized the state of the art on different available tests concerning their potential clinical applications for BC detection, prognosis, surveillance and response to therapy.
KW - Bladder cancer
KW - Free nucleic acids
KW - Liquid biopsy
KW - Urinary biomarkers
UR - http://www.scopus.com/inward/record.url?scp=85103814584&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103814584&partnerID=8YFLogxK
U2 - 10.3390/jpm11030237
DO - 10.3390/jpm11030237
M3 - Review article
AN - SCOPUS:85103814584
VL - 11
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
SN - 2075-4426
IS - 3
M1 - 237
ER -